PharVision Advisers’s Kontoor Brands KTB Stock Holding History

PharVision Advisers’s Portfolio KTB Stock Details KTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,918	Closed	-$249K	–	404
2024 Q4	$249K	Buy	+2,918	New	+$250K	0.21%	224

Other funds holding KTB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

PharVision Advisers's KTB Position: Q1 2025 in Review

PharVision Advisers sold out of Kontoor Brands (KTB) in Q1 2025, closing a stake of 2,918 shares — an estimated $249K sold.

PharVision Advisers first reported a position in KTB in Q4 2024 and held it in 1 quarter. The position peaked at $249K in Q4 2024. 387 funds tracked by Wall St. Rank hold KTB as of Q1 2025.

PharVision Advisers reported no remaining Kontoor Brands position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 2,918 Kontoor Brands shares in Q1 2025, an estimated $249K.
PharVision Advisers first reported a position in Kontoor Brands in Q4 2024 and held it in 1 quarter.
PharVision Advisers's Kontoor Brands position peaked at $249K in Q4 2024.
387 funds tracked by Wall St. Rank held Kontoor Brands as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.